External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Torrent Pharmaceuticals / Equity Bottom-Up

<ul><li>In its FY24 annual report, Torrent Pharma (TRP) has highlighted strategic themes that align with its short, medium and long-term goals: (1) improving market share in core markets (India, Brazil, Germany, and the US)</li><li>(2) investing in growth engines (capabilities in EMs)</li><li>3) operational excellence (cost competitiveness); (4) engaged and empowered stakeholders (productivity, innovation)</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

In its FY24 annual report, Torrent Pharma (TRP) has highlighted strategic themes that align with its short, medium and long-term goals: (1) improving market share in core markets (India, Brazil, Germany, and the US)(2) investing in growth engines (capabilities in EMs)3) operational excellence (cost competitiveness); (4) engaged and empowered stakeholders (productivity, innovation)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Torrent Pharma: Focus on branded generics and profitability. Maintain ADD

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Emcure Pharmaceuticals / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/emcure-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:35585:1" rel="noopener">Emcure Pharmaceuticals</a> is looking to raise around US$240m in its upcoming India IPO.</li>
<li>Emcure Pharmaceuticals (EP) is an Indian Pharmaceutical company engaged in the developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.</li>
<li>We have looked at the company’s past performance, in our earlier note. In this note, we talk about the RHP updates and take a quick look at valuations.</li>
</ul>



Emcure Pharmaceuticals is looking to raise around US$240m in its upcoming India IPO.
Emcure Pharmaceuticals (EP) is an Indian Pharmaceutical company engaged in the developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
We have looked at the company’s past performance, in our earlier note. In this note, we talk about the RHP updates and take a quick look at valuations.


Emcure Pharmaceuticals Pre-IPO - Refiling Updates and Valuations

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Emcure Pharmaceuticals seeks to raise INR19.5B in upcoming IPO through a fresh issue of INR8B and an OFS of 11.4M shares. IPO price band has been set at INR960–1,008.</li>
<li>The issue will open for subscription on July 3 and close on July 5. Bidding for anchor investors will open on July 2. Lot size for bidding is 14 shares.</li>
<li>IPO proceeds will be used to repay debt. As at March 31, 2024, the company’s outstanding borrowings stood at INR21B against cash balance of INR2B.  </li>
</ul>


Emcure Pharmaceuticals seeks to raise INR19.5B in upcoming IPO through a fresh issue of INR8B and an OFS of 11.4M shares. IPO price band has been set at INR960–1,008.
The issue will open for subscription on July 3 and close on July 5. Bidding for anchor investors will open on July 2. Lot size for bidding is 14 shares.
IPO proceeds will be used to repay debt. As at March 31, 2024, the company’s outstanding borrowings stood at INR21B against cash balance of INR2B.  


Emcure Pharmaceuticals Pre-IPO: IPO Price Band Set; Steep Valuation Offers Limited Upside Potential

Alkem Laboratories Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/alkem-laboratories-ltd" target="_blank" data-smartkarma-citation="entities:26928:1" rel="noopener">Alkem Laboratories Ltd (ALKEM IN)</a> reports 1% revenue growth in Q4FY24. However, gross margin improved significantly backed by lower raw material cost and lower intensity of price erosion in U.S.</li>
<li>For FY25, the company has guided for 10% YoY revenue growth, which is at par with the last five year’s average growth.</li>
<li>Alkem expects to maintain FY25 gross margin and EBITDA margin at the current level. As API prices have become mostly stable, there is limited room for further margin expansion.</li>
</ul>



Alkem Laboratories Ltd (ALKEM IN) reports 1% revenue growth in Q4FY24. However, gross margin improved significantly backed by lower raw material cost and lower intensity of price erosion in U.S.
For FY25, the company has guided for 10% YoY revenue growth, which is at par with the last five year’s average growth.
Alkem expects to maintain FY25 gross margin and EBITDA margin at the current level. As API prices have become mostly stable, there is limited room for further margin expansion.


Alkem Laboratories Ltd (ALKEM IN): Sluggish Performance Expected In Near-Term; Time to Book Profit

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hindalco-industries-ltd" target="_blank" data-smartkarma-citation="entities:18490:1" rel="noopener">Hindalco Industries (HNDL IN)</a> Postpones <a href="https://www.smartkarma.com/entities/novelis-corporation" target="_blank" data-smartkarma-citation="entities:39969:1" rel="noopener">Novelis Corporation (0620365D US)</a> IPO Amid Market Considerations</li>
<li>
<a href="https://www.smartkarma.com/entities/tata-motors-ltd" target="_blank" data-smartkarma-citation="entities:216:1" rel="noopener">Tata Motors Ltd (TTMT IN)</a>'s Tata Motors Finance to Merge with Tata Capital</li>
<li>
<a href="https://www.smartkarma.com/entities/national-stock-exchange" target="_blank" data-smartkarma-citation="entities:23751:1" rel="noopener">National Stock Exchange (NSEIN IN)</a> Sets World Record for Highest Number of Transactions in a Single Day</li>
</ul>



Hindalco Industries (HNDL IN) Postpones Novelis Corporation (0620365D US) IPO Amid Market Considerations

Tata Motors Ltd (TTMT IN)'s Tata Motors Finance to Merge with Tata Capital

National Stock Exchange (NSEIN IN) Sets World Record for Highest Number of Transactions in a Single Day


#8 India Insight: Novelis IPO Postponed, TMFL Merger, Angle One Client Growth, NSE World Record

India

Torrent Pharmaceuticals Ltd. manufactures bulk drugs and pharmaceutical formulations. The Company's formulations include cardio-vascular, psychotropic and anti-biotic drugs while its bulk drugs include atenolol, ciprofloxacin and norfloxacin. Torrent Pharmaceuticals has wholly owned subsidiaries in several regulated and less regulated international markets.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Torrent Pharmaceuticals (TRP IN)

Torrent Pharma: Focus on branded generics and profitability. Maintain ADD

In its FY24 annual report, Torrent Pharma (TRP) has highlighted strategic themes that align with its short, medium and long-term goals

HDFC Securities

Emcure Pharmaceuticals Pre-IPO - Refiling Updates and Valuations

Emcure Pharmaceuticals is looking to raise around US$240m in its upcoming India IPO. In this note, we talk about valuations.

Sumeet Singh

Emcure Pharmaceuticals Pre-IPO: IPO Price Band Set; Steep Valuation Offers Limited Upside Potential

Emcure Pharmaceuticals seeks to raise INR19.5B through fresh issue of INR8B and an OFS of 11.4M shares. The issue will open for subscription on...

Tina Banerjee

Alkem Laboratories Ltd (ALKEM IN): Sluggish Performance Expected In Near-Term; Time to Book Profit

Alkem reports just 1% revenue growth in Q4FY24, with significant improvement in gross margin. The company expects 10% YoY revenue growth for FY25,...

Tina Banerjee

#8 India Insight: Novelis IPO Postponed, TMFL Merger, Angle One Client Growth, NSE World Record

Hindalco Industries postpones Novelis Corporation IPO, Tata Motors Finance to merge with Tata Capital, NSE sets world record for transactions in a...

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Torrent Pharma: Focus on branded generics and profitability. Maintain ADD

In its FY24 annual report, Torrent Pharma (TRP) has highlighted strategic themes that align with its short, medium and long-term goals

HDFC Securities

Emcure Pharmaceuticals Pre-IPO - Refiling Updates and Valuations

Emcure Pharmaceuticals is looking to raise around US$240m in its upcoming India IPO. In this note, we talk about valuations.

Sumeet Singh

Emcure Pharmaceuticals Pre-IPO: IPO Price Band Set; Steep Valuation Offers Limited Upside Potential

Emcure Pharmaceuticals seeks to raise INR19.5B through fresh issue of INR8B and an OFS of 11.4M shares. The issue will open for subscription on...

Tina Banerjee

Alkem Laboratories Ltd (ALKEM IN): Sluggish Performance Expected In Near-Term; Time to Book Profit

​Alkem reports just 1% revenue growth in Q4FY24, with significant improvement in gross margin. The company expects 10% YoY revenue growth for FY25,...

Tina Banerjee

#8 India Insight: Novelis IPO Postponed, TMFL Merger, Angle One Client Growth, NSE World Record

​Hindalco Industries postpones Novelis Corporation IPO, Tata Motors Finance to merge with Tata Capital, NSE sets world record for transactions in a...

Sudarshan Bhandari

Alkem reports just 1% revenue growth in Q4FY24, with significant improvement in gross margin. The company expects 10% YoY revenue growth for FY25,...

Hindalco Industries postpones Novelis Corporation IPO, Tata Motors Finance to merge with Tata Capital, NSE sets world record for transactions in a...